About The Study: In this secondary analysis of the WISDOM trial, a randomized clinical trial that enrolled women without breast cancer ages 40 to 74, criteria-independent genetic testing in a pragmatic trial identified a substantial number of women with clinically actionable results, many of whom would not have qualified for genetic
testing under current guidelines. These findings support broader access to genetic testing as part of personalized breast cancer risk assessment.
Corresponding Author: To contact the corresponding author, Lisa Madlensky, PhD, email lmadlensky@health.ucsd.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2025.7323)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the San Antonio Breast Cancer Symposium.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.7323?guestAccessKey=29a68f19-f585-48fe-90ae-b2c0d131ce8e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=121225
JAMA Internal Medicine